glp 1 compounding news 🚨 FDA Cracks Down on Compounded GLP-1s – What's Next for Weight Loss? 🚨 Big in the weight loss world: The FDA is officially shutting down pharmacies producing GLP-1 medications FDA moves to stop compounding

Specific concerns for Crohn's patients include: Nausea and vomiting : May exacerbate existing symptoms or lead to dehydration, particularly concerning in patients with active disease Diarrhea : Difficult to differentiate from Crohn's-related diarrhea, potentially delaying recognition of disease flares Abdominal pain : May mask or mimic Crohn's-related pain, complicating clinical assessment Reduced oral intake : Appetite suppression combined with nausea may worsen nutritional deficiencies common in IBD Additional FDA-labeled risks include: Acute gallbladder disease : Cholelithiasis and cholecystitis occur more frequently with semaglutide, particularly with rapid weight loss Acute kidney injury : Dehydration from gastrointestinal side effects may lead to kidney injury Pancreatitis : Patients should be monitored for severe, persistent abdominal pain, sometimes radiating to the back Rare but serious gastrointestinal adverse events reported in post-marketing surveillance include cases of bowel obstruction and ileus

Combined with a strategic diet and exercise plan, GLP-1 for weight loss could be the thing that unlocks you in your weight loss journey

Then, when they sit down to an all-you-can-eat meal, (compared to individuals in the placebo group who had just gotten a squirt of water through the tube), they eat over 100 calories less

Forest plot of Lixisenatide versus comparators on the risk of overall Respiratory diseases

12 2025, Published 10:00 a.m

When you introduce a powerful GLP-1 agonist, you're amplifying a signal that the brain is already programmed to listen to